- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Psychosocial development.
Displaying page 1 of 2.
EudraCT Number: 2017-002225-38 | Sponsor Protocol Number: 331-201-00083 | Start Date*: 2018-02-23 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects with Bipolar I Disorder | |||||||||||||
Medical condition: Treatment of Manic Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012568-14 | Sponsor Protocol Number: 331-08-210 | Start Date*: 2009-11-18 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization | |||||||||||||
Full Title: A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients with Schizophrenia | |||||||||||||
Medical condition: schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003100-39 | Sponsor Protocol Number: NSGA | Start Date*: 2013-11-28 | |||||||||||
Sponsor Name:Dutch Growth Research Foundation | |||||||||||||
Full Title: Standardized versus individualized growth hormone treatment of short children born small for gestational age: Effects on short-term and longterm efficacy, long-term psychosocial development, gluc... | |||||||||||||
Medical condition: Children who are born small for gestational age, defined as a birth length and/or birth weight < -2 SD score, who fail to show catch-up growth (short stature). | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005601-46 | Sponsor Protocol Number: 000081 | Start Date*: 2013-05-15 | |||||||||||
Sponsor Name:Ferring International Pharmascience Center US, Inc. | |||||||||||||
Full Title: A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation | |||||||||||||
Medical condition: Chronic idiopathic constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) SK (Completed) HU (Completed) CZ (Completed) GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000963-25 | Sponsor Protocol Number: A1481156 | Start Date*: 2005-05-30 | |||||||||||
Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent, UK | |||||||||||||
Full Title: A Multicenter, Long-Term Extension Study to Assess Safety of Oral Sildenafil in the Treatment of Subjects Who Have Completed Study A1481131 | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) FI (Prematurely Ended) SK (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002738-22 | Sponsor Protocol Number: 62388 | Start Date*: 2018-03-02 | |||||||||||
Sponsor Name:Princess Máxima Center of Pediatric Oncology | |||||||||||||
Full Title: Double blind placebo controlled randomized intervention study to validate the beneficial effect of hydrocortisone on dexamethasone-induced neurobehavioral side effects in pediatric acute lymphoblas... | |||||||||||||
Medical condition: Acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003556-31 | Sponsor Protocol Number: SHP-607-201 | Start Date*: 2015-02-10 |
Sponsor Name:Premacure AB, A Member of the Shire Group of Companies | ||
Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | ||
Medical condition: Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-015242-30 | Sponsor Protocol Number: 2009-001 | Start Date*: 2009-11-05 |
Sponsor Name:The Walton Centre for Neurology and Neurosurgery NHS Trust | ||
Full Title: An open study to compare the efficacy of immunoglobulin administered subcutaneoulsy (SCIG) with current best practice in patients with Complex Regional Pain Syndrome (CRPS) | ||
Medical condition: Complex Regional Pain Syndrome (CRPS) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000590-75 | Sponsor Protocol Number: betami_vs_1.0 | Start Date*: 2018-05-31 |
Sponsor Name:Oslo University Hospital | ||
Full Title: BEta-Blocker Treatment after Acute Myocardial Infarction in revascularized patients with preserved left ventricular systolic function (BETAMI trial) | ||
Medical condition: Patients admitted to hospital with acute myocardial infarction treated With reperfusion therapy (i.e trombolysis or percutaneous coronary intervention) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001459-30 | Sponsor Protocol Number: 331-10-236 | Start Date*: 2019-03-07 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc | |||||||||||||
Full Title: A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Ongoing) PL (Completed) BG (Prematurely Ended) FR (Ongoing) IT (Completed) RO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002726-84 | Sponsor Protocol Number: SHP607-203 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Premacure AB | |||||||||||||
Full Title: Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants | |||||||||||||
Medical condition: Chronic Lung Disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003787-48 | Sponsor Protocol Number: BP41674 | Start Date*: 2020-06-11 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche | |||||||||||||
Full Title: AN OPEN-LABEL, MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7248824 IN PARTICIPANTS WITH ANGELMAN SYNDROME | |||||||||||||
Medical condition: Angelman Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004298-24 | Sponsor Protocol Number: KCH-STR-INF | Start Date*: 2008-08-13 | |||||||||||
Sponsor Name:King's College Hospital NHS Foundation Trust [...] | |||||||||||||
Full Title: A cluster randomised trial of different strategies of antibiotic use to reduce the incidence and consequences of chest infection in acute stroke patients with swallowing problems. | |||||||||||||
Medical condition: Acute stroke patients with dysphagia and at high risk of aspiration as assessed by the bedside swallowing assessment. A policy to prevent pneumonias with prophylactic antibiotics is being investig... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004593-29 | Sponsor Protocol Number: Uni-Koeln-1495 | Start Date*: 2016-01-19 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma | |||||||||||||
Medical condition: recurrent or progressive high-risk Neuroblastoma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000531-32 | Sponsor Protocol Number: NN8640-4172 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A randomised, multinational, active-controlled,(open-labelled), dose finding, (double-blinded), parallel group trial investigating efficacy and safety of once-weekly NNC0195-0092 treatment compared... | |||||||||||||
Medical condition: Growth hormone deficiency in children | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) SE (Completed) SI (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004471-31 | Sponsor Protocol Number: I4V-MC-JAHX | Start Date*: 2019-06-13 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA) | |||||||||||||
Medical condition: Juvenile Idiopathic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002675-27 | Sponsor Protocol Number: 31-07-246 | Start Date*: 2009-05-11 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Ma... | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000069-57 | Sponsor Protocol Number: P15-01 | Start Date*: 2017-07-21 | |||||||||||
Sponsor Name:BIOPROJET PHARMA | |||||||||||||
Full Title: A Multisite Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment | |||||||||||||
Medical condition: Male or female with moderate or severe DSM-5 alcohol use disorder (based on the alcohol use disorders section of MINI) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002592-34 | Sponsor Protocol Number: RID-TB:Dx | Start Date*: 2020-08-28 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Research to Improve the Detection and Treatment of Latent Tuberculosis Infection: Diagnostics (RID-TB:Dx) A randomised controlled trial to evaluate the effectiveness of using the RD-1 based C Tb s... | |||||||||||||
Medical condition: Latent Tuberculosis infection (LTBI) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000598-95 | Sponsor Protocol Number: HS-20-674 | Start Date*: 2021-07-30 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
